Home
About
- Overview
- Team
- Investors
Science
Pipeline
Partners
News & Events
Contact
Menu Menu

Disease-modifying treatment for ALS enters Phase I

26 January 2026

Drug Discovery World

https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Shutterstock_657435445-1200x800-c-default.jpg 800 1200 Webadm https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png Webadm2026-01-26 08:01:292026-08-14 13:36:48Disease-modifying treatment for ALS enters Phase I

Terms & Conditions
Privacy Policy

Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical ...

Founder-CEO Interview Series

Scroll to top